Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

NCT03755193 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
DRUG: Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
DRUG: ELD "Edirol®Tablet 0.75ug"

Sponsor

Shinshu University